Toronto Dominion Bank Grows Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Toronto Dominion Bank boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 17,298.3% in the second quarter, Holdings Channel.com reports. The fund owned 20,704 shares of the company’s stock after buying an additional 20,585 shares during the quarter. Toronto Dominion Bank’s holdings in Teva Pharmaceutical Industries were worth $336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. New Covenant Trust Company N.A. purchased a new position in Teva Pharmaceutical Industries during the 1st quarter worth $28,000. EntryPoint Capital LLC acquired a new position in Teva Pharmaceutical Industries during the 1st quarter worth approximately $30,000. Beach Investment Counsel Inc. PA purchased a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $48,000. Byrne Asset Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $52,000. Finally, GAMMA Investing LLC grew its stake in Teva Pharmaceutical Industries by 105.7% in the 2nd quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock valued at $55,000 after acquiring an additional 1,741 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $18.02 on Tuesday. The stock’s 50 day moving average is $17.76 and its two-hundred day moving average is $16.25. Teva Pharmaceutical Industries Limited has a 52-week low of $8.06 and a 52-week high of $19.08. The company has a market capitalization of $20.42 billion, a PE ratio of -43.95, a P/E/G ratio of 1.21 and a beta of 0.88. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.03. The firm had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. Analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of recent research reports. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Barclays lifted their price objective on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Jefferies Financial Group raised their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Wednesday, July 10th. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 23rd. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $18.89.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the sale, the insider now directly owns 45,060 shares in the company, valued at $777,285. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.